Willow Biosciences Inc. Stock price

Equities

WLLW

CA97111B4047

Pharmaceuticals

End-of-day quote Toronto S.E. 07:00:00 2024-03-26 pm EDT 5-day change 1st Jan Change
0.095 CAD -5.00% Intraday chart for Willow Biosciences Inc. +5.56% -5.00%
Sales 2021 0.13 0.18 Sales 2022 0.82 1.11 Capitalization 14.23M 19.27M
Net income 2021 -6M -8.13M Net income 2022 -14M -18.96M EV / Sales 2021 192,476,654 x
Net cash position 2021 30M 40.63M Net cash position 2022 15.01M 20.32M EV / Sales 2022 -947,916 x
P/E ratio 2021
-8.79 x
P/E ratio 2022
-0.96 x
Employees 32
Yield 2021 *
-
Yield 2022
-
Free-Float 72.66%
More Fundamentals * Assessed data
Dynamic Chart
Willow Biosciences Announces Second Strategic Investment From Kalsec MT
Willow Biosciences Secures Strategic Investment From Kalsec to Develop Natural Food Ingredient MT
Willow Biosciences Inc. announced that it expects to receive funding from Kalsec Inc. CI
Willow Biosciences Enters Partnership With Global Ingredient Manufacturer MT
Willow Biosciences Inc. Announces Collaboration with Global Active Pharmaceutical Ingredient Manufacturer to Develop A More Sustainable, Cost-Effective Manufacturing Process for A Large Volume Global Market CI
Willow Biosciences Announces Collaboration with Active Pharmaceutical Ingredient Manufacturer to Manufacture More Sustainable, Cost-Effective Manufacturing Route for Their Largest Product Sold Globally CI
Willow Biosciences Announces Collaboration With Enterin MT
Willow Biosciences Inc. Announces Collaboration with Enterin, Inc. to Develop Sustainable Interimates and Active Pharmaceutical Ingredients CI
Willow Biosciences Highlights Growth Plans for 2024, Provides 2023 Highlights MT
Willow Biosciences Brief: Says Plans For "Significant" Growth In 2024 MT
Toronto Stocks Flat; Laurentian Bank of Canada Declines on Lower 4Q Profit, Revenue DJ
Willow Biosciences and Nasdaq-listed Biopharma Co Advancing Development Program MT
Willow Biosciences Brief: Willow and a Nasdaq-listed biopharma company Advancing Development Program MT
Willow Biosciences Reports Q3 Results, Provides Update MT
North American Morning Briefing : Stocks Seen -2- DJ
More news
1 day-5.00%
1 week+5.56%
Current month-17.39%
1 month-20.83%
3 months-5.00%
6 months+11.76%
Current year-5.00%
More quotes
1 week
0.09
Extreme 0.085
0.10
1 month
0.08
Extreme 0.08
0.12
Current year
0.08
Extreme 0.08
0.14
1 year
0.06
Extreme 0.06
0.18
3 years
0.06
Extreme 0.06
1.55
5 years
0.00
Extreme 0
5.25
10 years
0.00
Extreme 0
5.25
More quotes
Managers TitleAgeSince
Chief Executive Officer - 19-04-11
Director of Finance/CFO - 19-04-11
Chief Tech/Sci/R&D Officer - 19-03-31
Members of the board TitleAgeSince
Chairman 63 23-02-20
Director/Board Member 63 19-04-11
Director/Board Member 51 19-04-11
More insiders
Date Price Change Volume
24-03-27 0.095 -5.00% 9,500
24-03-26 0.1 +5.26% 4,000
24-03-25 0.095 +5.56% 226,608
24-03-22 0.09 0.00% 171,000
24-03-21 0.09 0.00% 22,001

End-of-day quote Toronto S.E., March 26, 2024

More quotes
Willow Biosciences Inc. is a Canada-based biotechnology company. The Company develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Its FutureGrown biotechnology platform allows production with sustainability at its core. Its commercial product, Cannabigerol CBG, which is a cannabinoid that has anti-microbial, anti-inflammatory, and antioxidant properties. It also offers BioOxi, a bio-oxidation technology platform. By leveraging BioOxi, commercial partners can revolutionize manufacturing of oxygenated and hydroxylated functional ingredients, such as steroids, polyphenols, oxyterpenes and certain other targeted ingredients produced from such methods. It is also developing BioOxi-based process for production of the generic active pharmaceutical ingredient (API), hydrocortisone, and its derivatives. Its other pipeline products include Ursodeoxycholic acid (UCAC), Astaxanthin, B-carotene and others.
More about the company
  1. Stock
  2. Equities
  3. Stock Willow Biosciences Inc. - Toronto S.E.